We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sucampo Pharmaceuticals is paying $278 million to acquire Japanese drugmaker R-Tech Ueno, which manufactures the constipation drug Amitiza for Sucampo and its commercialization partners, Takeda, Mylan and Harbin Gloria Pharmaceuticals. Read More
California drugmaker Medivation is acquiring the worldwide rights to BioMarin’s breast cancer drug talazoparib, in a move aimed at diversifying and expanding its global oncology footprint. Read More
AstraZeneca and Peregrine Pharmaceuticals are collaborating on an early-phase clinical trial to evaluate the safety and efficacy of two novel investigational drugs in patients with a range of solid tumor types. Read More
The FDA has granted rare pediatric disease designation to two investigational Duchenne Muscular Dystrophy therapies — Sarepta Therapeutics’ eteplirsen and BioMarin Pharmaceutical’s drisapersen — the first DMD candidates to win the designation. Read More
Sandoz and Amgen are separately asking the full Federal Circuit Court of Appeals to review a July decision by a three-judge panel on the biosimilar approval pathway, saying the ruling is contrary to Congress’ intent in the Biologics Price Competition and Innovation Act. Read More